Factor Model (net +1.5)
Factor Model
net +1.5 4.1 / 10Phase 3 trial pause tanks stock 53.56% in one day
Watch: Watch for an SEC filing or investor call explaining the pause rationale and expected timeline for resumption or discontinuation. Safety data becomes the critical variable — any hint of adverse events will keep the stock under pressure.
Aardvark Therapeutics voluntarily paused its Phase 3 Hunger Elimination or Reduction Objective trial on March 2, triggering a 53.56% single-day stock collapse. The company hasn't disclosed the rationale for the pause or timeline for resolution. This represents a critical setback to the development pipeline — a Phase 3 halt is rare and typically signals safety, efficacy, or enrollment issues that could threaten the entire program.
A Phase 3 pause is clinical catastrophe territory. The trial was likely the cornerstone of near-term value; without it, the company has no near-term value catalyst and faces a multi-year reset if the trial resumes at all. Investors are pricing in worst-case scenarios until management clarifies the pause reason.
Evidence
3 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when AARD changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.